Your browser is no longer supported. Please, upgrade your browser.
Settings
ICPT Intercept Pharmaceuticals, Inc. daily Stock Chart
ICPT [NASD]
Intercept Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-12.40 Insider Own2.80% Shs Outstand31.01M Perf Week-5.62%
Market Cap3.18B Forward P/E- EPS next Y-8.48 Insider Trans-6.57% Shs Float21.75M Perf Month3.27%
Income-332.50M PEG- EPS next Q-2.51 Inst Own70.70% Short Float14.19% Perf Quarter-0.66%
Sales164.20M P/S19.40 EPS this Y14.10% Inst Trans-0.02% Short Ratio7.12 Perf Half Y46.46%
Book/sh3.24 P/B31.70 EPS next Y19.00% ROA-65.20% Target Price135.03 Perf Year71.45%
Cash/sh15.77 P/C6.51 EPS next 5Y-8.89% ROE-644.10% 52W Range51.05 - 133.74 Perf YTD75.80%
Dividend- P/FCF- EPS past 5Y-14.30% ROI-90.20% 52W High-23.21% Beta-0.93
Dividend %- Quick Ratio6.00 Sales past 5Y121.70% Gross Margin98.60% 52W Low101.18% ATR6.49
Employees507 Current Ratio6.00 Sales Q/Q13.80% Oper. Margin- RSI (14)48.87 Volatility8.01% 6.93%
OptionableYes Debt/Eq3.83 EPS Q/Q24.70% Profit Margin- Rel Volume0.81 Prev Close100.88
ShortableYes LT Debt/Eq3.83 EarningsOct 31 BMO Payout- Avg Volume433.40K Price102.70
Recom2.40 SMA203.44% SMA50-5.06% SMA20019.08% Volume349,989 Change1.80%
Oct-02-18Downgrade Raymond James Strong Buy → Outperform
Oct-01-18Resumed Cantor Fitzgerald Overweight $170
Sep-12-18Initiated ROTH Capital Buy $192
Aug-15-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-06-18Upgrade Goldman Sell → Buy
Aug-03-18Downgrade Laidlaw Buy → Hold $90 → $95
Jun-28-18Initiated Raymond James Strong Buy
Feb-07-18Downgrade Goldman Neutral → Sell
Nov-01-17Upgrade Laidlaw Hold → Buy $90
Nov-01-17Upgrade Cantor Fitzgerald Underweight → Neutral $69
Oct-06-17Resumed Goldman Neutral
Oct-04-17Reiterated RBC Capital Mkts Outperform
Oct-04-17Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-17Reiterated RBC Capital Mkts Outperform $200 → $244
Sep-22-17Reiterated Laidlaw Hold $118 → $90
Sep-22-17Downgrade Citigroup Buy → Neutral
Sep-21-17Downgrade Wells Fargo Outperform → Market Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $244
Jul-11-17Initiated Jefferies Buy
May-05-17Upgrade Laidlaw Sell → Hold $115
Nov-16-18 07:15PM  Intercept Pharmaceuticals Inc (ICPT) President & CEO Mark Pruzanski Sold $5.1 million of Shares GuruFocus.com
07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and bluebird bio ACCESSWIRE
Nov-13-18 08:00AM  Why Viking Therapeutics Stock Is Bolting Higher Today Motley Fool
Nov-12-18 03:16PM  5 Pharma Stocks to Stay Away From InvestorPlace -7.39%
09:24AM  Why Intercept Pharmaceuticals, Inc. Stock Broke Down in October Motley Fool
Nov-08-18 09:35PM  Edited Transcript of ICPT earnings conference call or presentation 31-Oct-18 12:30pm GMT Thomson Reuters StreetEvents
07:05AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Seattle Genetics ACCESSWIRE
Nov-05-18 07:00AM  Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018 GlobeNewswire
Nov-01-18 07:34AM  Intercept (ICPT) Gains on Earnings and Revenue Beat in Q3 Zacks +10.26%
Oct-31-18 08:55AM  Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates Zacks +10.09%
07:50AM  Intercept: 3Q Earnings Snapshot Associated Press
07:27AM  Intercept Pharma stock rises 3.2% on narrower-than-expected Q3 loss MarketWatch
07:05AM  Intercept Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Oct-27-18 07:18AM  Better Buy: Intercept Pharmaceuticals Inc. vs. Madrigal Pharmaceuticals Motley Fool
07:00AM  Where Will Gilead Sciences, Inc. Be in 5 Years? Motley Fool
Oct-25-18 09:21AM  3 Top Mid-Cap Stocks to Buy Immediately Motley Fool
Oct-24-18 04:05PM  Intercept to Announce Third Quarter 2018 Financial Results on October 31, 2018 GlobeNewswire -7.43%
07:50AM  Report: Developing Opportunities within Vitamin Shoppe, Intercept Pharmaceuticals, Viasat, Team, Valvoline, and ViewRay Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-17-18 02:27PM  5 Beaten-Down Biotech Stocks to Pick Up from the Wreckage InvestorPlace
Oct-16-18 03:01PM  Can This Tiny Biotech Revolutionize a $35 Billion Market? Motley Fool +6.00%
10:00AM  Forget Gilead Sciences: Intercept Pharmaceuticals, Inc. Is a Better Growth Stock Motley Fool
Oct-11-18 09:00AM  Why Intercept Pharmaceuticals, Inc. Stock Raced Higher in September Motley Fool
Sep-27-18 06:00AM  3 Biotechs Poised for 10% Gains Investopedia
Sep-26-18 07:05AM  Intercept to Present at Upcoming Investor Conference GlobeNewswire
Sep-12-18 09:17AM  3 Top Stocks for Investing in Pharma's Next $35 Billion Market Motley Fool
Sep-11-18 05:14PM  Here's Why Intercept Pharmaceuticals Jumped 22.7% in August Motley Fool
Sep-10-18 08:00AM  Today's Research Reports on Trending Tickers: Amicus Therapeutics and Intercept Pharmaceuticals ACCESSWIRE
Aug-29-18 07:05AM  Intercept to Present at Upcoming Investor Conferences GlobeNewswire
Aug-22-18 08:00AM  Today's Research Reports on Trending Tickers: Array BioPharma and Intercept Pharmaceuticals ACCESSWIRE
Aug-17-18 09:54AM  Is Intercept Pharmaceuticals, Inc. a Buy? Motley Fool
Aug-14-18 09:40AM  Edited Transcript of ICPT earnings conference call or presentation 2-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-18 02:00PM  4 Biotech Stocks That May Fall By as Much as 13% Investopedia
Aug-09-18 06:32AM  2 Growth Stocks That Could Make You Rich Motley Fool
Aug-07-18 08:00AM  Todays Research Reports on Stocks to Watch: Protagonist Therapeutics and Intercept Pharmaceuticals ACCESSWIRE
Aug-06-18 03:45PM  Why Intercept Pharmaceuticals Stock Is Moving Higher Today Motley Fool +17.94%
12:44PM  Intercept Pharma Notches 2 Upgrades On Ocaliva Prospects Benzinga
11:59AM  Small Biotechs See Big Gains as Bluebird, Intercept Fly Barrons.com
Aug-03-18 09:19AM  Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers Zacks
Aug-02-18 03:06PM  Intercept Shares Rise as Drug Sales Recover After Patient Deaths Bloomberg +9.86%
09:47AM  Intercept (ICPT) Q2 Loss Narrower-Than-Expected Zacks
07:31AM  Intercept: 2Q Earnings Snapshot Associated Press
07:05AM  Intercept Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-30-18 03:32PM  What's in Store for Intercept (ICPT) This Earnings Season? Zacks
Jul-26-18 04:05PM  Intercept to Announce Second Quarter 2018 Financial Results on August 2, 2018 and Present at Upcoming Investor Conference GlobeNewswire
Jul-25-18 08:20AM  Report: Developing Opportunities within Clearwater Paper, Intercept Pharmaceuticals, Community Trust, Community Bank System, Laboratory Corporation of America, and Dicerna Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire
Jul-23-18 06:00AM  3 Hot Biotech Stocks With More Gains Ahead Investopedia
Jul-19-18 03:08PM  5 Biotech Stocks Well Poised to Beat Q2 Earnings Estimates Zacks
Jul-16-18 07:10AM  Complimentary Technical Snapshots on Intercept Pharma and Three More Biotech Stocks ACCESSWIRE
Jul-14-18 07:16AM  3 Biotech Stocks With Big News Coming in NASH Motley Fool
Jul-03-18 08:10AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and MyoKardia ACCESSWIRE
Jun-26-18 07:06AM  This Is the Most Undervalued NASH Drug Stock, and Wall Street Is Ignoring It Motley Fool
Jun-20-18 08:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Array BioPharma ACCESSWIRE
Jun-18-18 11:45AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-14-18 09:23AM  NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
Jun-13-18 08:20AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Intercept Pharmaceuticals ACCESSWIRE
Jun-11-18 08:00AM  Todays Research Reports on Stocks to Watch: TapImmune and Intercept Pharmaceuticals ACCESSWIRE
Jun-07-18 05:00PM  Intercept to Present at Upcoming Conference GlobeNewswire
08:35AM  Intercept (ICPT) Up 3.8% Since Earnings Report: Can It Continue? Zacks
Jun-01-18 12:16PM  3 Biotech Stocks Poised for 12% Gains Investopedia +5.83%
10:08AM  Madrigal's NASH Study Data Encouraging, Stock Skyrockets Zacks
May-31-18 04:02PM  Madrigal Pharma Shares Double After Successful Phase II Results For Fatty Liver Drug Forbes
08:49AM  Madrigal Threatens Intercept's Lead in Fatty Liver Disease Bloomberg
May-29-18 12:13PM  Pharma Companies Race to Find Wonder Drug for Obesity-Linked Liver Disease Bloomberg
May-18-18 08:30AM  Report: Developing Opportunities within AG Mortgage Investment Trust, Associated Banc-Corp, Reata Pharmaceuticals, Nathan's Famous, United Fire Group, and Intercept Pharmaceuticals Future Expectations, Projections Moving into 2018 GlobeNewswire
May-14-18 06:00AM  4 Biotech Stocks Set to Rise By 14% or More Investopedia
May-11-18 08:07AM  Edited Transcript of ICPT earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-08-18 09:59AM  Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag Zacks
07:31AM  Intercept: 1Q Earnings Snapshot Associated Press
07:05AM  Intercept Pharmaceuticals Announces First Quarter 2018 Financial Results, Issues 2018 Ocaliva Net Sales Guidance and Provides Business Update GlobeNewswire
May-01-18 05:00PM  Intercept to Announce First Quarter 2018 Financial Results on May 8, 2018 and Present at Upcoming Investor Conferences GlobeNewswire
Apr-30-18 06:19PM  What's in Store for Intercept (ICPT) This Earnings Season? Zacks
Apr-24-18 08:00AM  Intercept Pharmaceuticals Appoints Nancy Miller-Rich to Its Board of Directors GlobeNewswire
Apr-15-18 06:05PM  Insider Buys Of The Week: Intercept Pharmaceuticals, Macy's And More Benzinga
Apr-13-18 07:00AM  Liver Biopsy Data from POISE Phase 3 Substudy Supports Obeticholic Acids Ability to Reverse or Stabilize Fibrosis and Cirrhosis in Primary Biliary Cholangitis (PBC) Patients GlobeNewswire
Apr-11-18 04:29PM  Could This Tiny Biotech Rout Intercept In Liver Disease Drugs? Investor's Business Daily -6.63%
Apr-08-18 07:19AM  4 Top Stocks for Investing in Pharma's Next $35 Billion Market Motley Fool
Apr-06-18 09:39AM  3 High-Growth Stocks That Could Soar Motley Fool
08:42AM  Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Intercept Pharmaceuticals and Conatus Pharmaceuticals ACCESSWIRE
Apr-05-18 04:32PM  Why Tesla, Marathon Oil, and Intercept Pharmaceuticals Jumped Today Motley Fool +9.94%
01:38PM  Why Doesn't Gilead Just Buy Intercept Pharmaceuticals Already? Motley Fool
08:30AM  Intercept Pharmaceuticals Announces Pricing of Upsized $250 Million Public Offering and Concurrent Private Placement of Common Stock GlobeNewswire
08:06AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
Apr-04-18 04:05PM  Intercept Pharmaceuticals Announces Proposed $120 Million Public Offering and Concurrent $92 Million Private Placement of Common Stock GlobeNewswire
Mar-27-18 07:00AM  Blog Exposure - Intercept Pharma to Present Multiple New Ocaliva Data at International Liver Congress 2018 ACCESSWIRE
Mar-26-18 04:30PM  Intercept to Present at Upcoming Conference GlobeNewswire
Mar-23-18 07:00AM  Intercept Announces Multiple New Ocaliva® (obeticholic acid) Data Presentations at the International Liver Congress 2018 GlobeNewswire
Mar-21-18 11:25AM  Edited Transcript of ICPT earnings conference call or presentation 14-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
08:30AM  New Research: Key Drivers of Growth for LTC Properties, NACCO Industries, Viad, Resource Capital, WageWorks, and Intercept Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Mar-16-18 11:44AM  Intercept (ICPT) Up 6.7% Since Earnings Report: Can It Continue? Zacks
Mar-13-18 05:48PM  CORRECTING and REPLACING -- Intercept to Present at Upcoming Conference GlobeNewswire
05:00PM  Intercept to Present at Upcoming Conference GlobeNewswire
Mar-08-18 09:30AM  2 Cheap Growth Stocks to Buy Right Now Motley Fool
Feb-15-18 08:02AM  Intercept (ICPT) Q4 Earnings & Sales Lag on Dull Ocaliva Zacks +8.25%
Feb-14-18 09:09AM  Is Intercept Pharmaceuticals Incs (NASDAQ:ICPT) CEO Incentives Align With Yours? Simply Wall St.
08:41AM  Intercept (ICPT) Misses on Q4 Earnings & Sales Zacks
08:05AM  Intercept reports 4Q loss Associated Press
07:05AM  Intercept Pharmaceuticals Reports Full Year and Fourth Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Feb-13-18 08:16AM  Intercept Starts OCA Trial for NASH Patients With Cirrhosis Zacks
Feb-12-18 08:02AM  Will Ocaliva Sales Dampen Intercept's (ICPT) Q4 Earnings? Zacks
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pruzanski MarkPresident & CEONov 16Option Exercise8.6727,606239,253594,411Nov 16 07:00 PM
Pruzanski MarkPresident & CEONov 16Sale101.5427,6062,803,129566,805Nov 16 07:00 PM
Pruzanski MarkPresident & CEONov 15Option Exercise8.6722,394194,082589,199Nov 16 07:00 PM
Pruzanski MarkPresident & CEONov 15Sale100.5022,3942,250,585566,805Nov 16 07:00 PM
Shapiro DavidChief Medical OfficerNov 01Option Exercise21.502,00043,00041,152Nov 02 07:01 PM
Shapiro DavidChief Medical OfficerNov 01Sale96.322,000192,64039,152Nov 02 07:01 PM
Shapiro DavidChief Medical OfficerOct 15Option Exercise21.503,42573,63842,577Oct 16 07:00 PM
Shapiro DavidChief Medical OfficerOct 15Sale102.953,425352,60439,152Oct 16 07:00 PM
Shapiro DavidChief Medical OfficerOct 05Sale110.6575983,98339,152Oct 05 07:01 PM
Shapiro DavidChief Medical OfficerSep 05Sale111.434,917547,89142,196Sep 07 06:00 PM
Gottesdiener Keith MichaelDirectorApr 09Buy64.001,17174,9445,001Apr 09 07:37 PM
BRADBURY DANIELDirectorApr 09Buy64.007,812499,96811,642Apr 09 07:36 PM
Pruzanski MarkCEO & PresidentApr 09Buy64.007,812499,968576,564Apr 09 07:36 PM
Genextra S.p.A.10% OwnerApr 09Buy64.00390,62525,000,0006,845,578Apr 09 05:20 PM
Micheli Francesco10% OwnerApr 09Buy64.00390,62525,000,0006,845,578Apr 09 05:19 PM